Condition
Multiple Sclerosis, Secondary Progressive
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 35 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
35 shownEffects of Acute Intermittent Hypoxia on Neuroplasticity in MSNCT06390930 · 2025-02-01
RECRUITINGClinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)NCT06526364 · 2024-12-10
RECRUITINGIntermittent Hypoxia in Persons With Multiple SclerosisNCT06276634 · 2024-04-30
RECRUITINGA Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple SclerosisNCT06138132 · 2024-04-10
RECRUITINGCladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).NCT05961644 · 2022-10-03
RECRUITINGMS-ResearchBiomarkerSNCT05204459 · 2021-11-11
RECRUITINGA Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple SclerosisNCT06900192 · 2025-03-01
NOT_YET_RECRUITINGPET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPFNCT06683612 · 2024-12-09
COMPLETEDThe Synergistic Effects of AIH and FES in Persons With MSNCT06413602 · 2024-11-01
ACTIVE_NOT_RECRUITINGKYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple SclerosisNCT06384976 · 2024-09-20
ACTIVE_NOT_RECRUITINGDevelopment of Camera Based Gait Quality Measure for Persons With Multiple SclerosisNCT06516458 · 2024-07-01
UNKNOWNThe Effects of In-phase Bilateral Exercise in People with Progressive Multiple SclerosisNCT06436131 · 2023-10-02
COMPLETEDAn Observational Biomarker Study in Multiple Sclerosis (MS) PatientsNCT05663853 · 2023-03-28
COMPLETEDMUSCLE - Nordic Walking in MUltiple SCLErosisNCT05385731 · 2022-08-02
UNKNOWNExercise Effects in Multiple SclerosisNCT05496881 · 2022-06-15
UNKNOWNNovel Imaging Markers in SPMSNCT05357833 · 2022-06-01
COMPLETEDSafety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple SclerosisNCT05168384 · 2022-03-26
COMPLETEDNeuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple SclerosisNCT05122559 · 2022-02-16
ACTIVE_NOT_RECRUITINGMotor Asymmetry in Progressive Multiple Sclerosis PatientsNCT04918225 · 2021-11-03
COMPLETEDHydroxychloroquine and Indapamide in SPMSNCT05013463 · 2021-10-01
UNKNOWNDiscontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).NCT04260711 · 2020-07-01
UNKNOWNPhase II Clinical Trial of OCH-NCNP1NCT04211740 · 2019-12-06
COMPLETEDSensitivity of Motor Assessment in MS - a Prospective Cohort StudyNCT04993274 · 2019-02-20
UNKNOWNCortical Lesions in Patients With Multiple SclerosisNCT03653585 · 2018-09-04
COMPLETEDIntranasal Insulin for Improving Cognitive Function in Multiple SclerosisNCT02988401 · 2017-12-01
COMPLETEDOpen-label Study of Liothyronine in MSNCT02506751 · 2015-07-01
COMPLETEDBG00012 and Delay of Disability Progression in Secondary Progressive Multiple SclerosisNCT02430532 · 2015-05-01
TERMINATEDDomperidone in Secondary Progressive Multiple Sclerosis (SPMS)NCT02308137 · 2015-02-01
COMPLETEDEfficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MSNCT02273635 · 2014-09-01
UNKNOWNSafety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple SclerosisNCT01982942 · 2013-11-01
COMPLETEDImaging of Intracerebral Inflammation in MSNCT02305264 · 2012-03-19
COMPLETEDEfficacy and Safety of Masitinib in the Treatment of Progressive Multiple SclerosisNCT01433497 · 2011-08-01
COMPLETEDBayer/Cognitive Assessments With Multiple Sclerosis SubjectsNCT00888277 · 2009-05-01
COMPLETEDEfficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple SclerosisNCT00468611 · 2007-06-01
TERMINATEDDose-Escalation Study of T Cell Vaccine in Multiple SclerosisNCT00587691 · 2002-07-01
COMPLETEDCommon interventions
PlaceboDRUG4Acute Intermittent HypoxiaOTHER3Standard lymphodepletion regimenDRUG20.9% Chloride Injection SodiumDRUG118F-DPA-714 and 18F-FDGDRUG1All participants will be asked to provide data and samples for collection and analysis.OTHER1AndrographolidesDRUG1Anti-CD20 mABDRUG1Camera Based Kinematic AnalysisDIAGNOSTIC_TEST1Cladribine Subcutaneous InjectionDRUG1Conservative exercisesBEHAVIORAL1dimethyl fumarateDRUG1DMTDRUG1DomperidoneDRUG1Exercise Group 1OTHER1Exercise Group 2OTHER1Exercise Group 3OTHER1Extracorporeal PhotopheresisCOMBINATION_PRODUCT1Ferumoxytol infusionDRUG1Free Walking (FWG)OTHER1GadoteridolDRUG1Health Education (HEG)OTHER1Hydroxychloroquine PillDRUG1ibudilastDRUG1In-phase Bilateral ExerciseBEHAVIORAL1
Leading sponsors
Shirley Ryan AbilityLab
4
Johns Hopkins University
2
Stanford University
2
University of Calgary
2
AB Science
1
Abu Dhabi Stem Cells Center
1
Amsterdam UMC, location VUmc
1
Assistance Publique - Hôpitaux de Paris
1
Biogen
1
BioMS Technology Corp.
1
Cedars-Sinai Medical Center
1
Contineum Therapeutics
1
Cyprus University of Technology
1
Danish Research Centre for Magnetic Resonance
1
Emmanuelle Waubant, MD PhD
1
Trial status mix
COMPLETED16
UNKNOWN7
RECRUITING6
ACTIVE_NOT_RECRUITING3
TERMINATED2
NOT_YET_RECRUITING1
Phase mix
PHASE211
NA8
PHASE18
PHASE34
EARLY_PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.